ClinicalTrials.gg
RecruitingNCT06609005Updated Jun 4, 2026

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

A Phase 1/2 interventional study of INV-9956 in Advanced Metastatic Castration Resistant Prostate Cancer, sponsored by Shenzhen Ionova Life Sciences Co., Ltd.. Recruiting at 22 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Shenzhen Ionova Life Sciences Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
240th of 436
84 · median 100
Started
2025
with 77 others
Phase 1/2
52 of 542
30 open now
Primary completion
2028-01
later than 261 of 341 live
Registered
330th of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 240th largest by planned enrollment of the 436 interventional ones that give a count, is one of 78 that started in 2025, is one of 52 in phase 1/2, reaches primary completion later than 261 of the 341 other live ones, and was the 330th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.

Read the detailed description

This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.

The entire study consists of two parts: Phase 1 for dose escalation and Phase 2 for dose expansion.

Phase 1 dose escalation of INV-9956 follows a real time monitored, PK/PD and safety guided scheme with a traditional 3+3 design for DLT assessment.

Phase 2 aims to reassure the safety profile and better define efficacy. Phase 2 consists of up to 2 cohorts by different AR gene status:

  • Cohort A: AR mutant CRPC
  • Cohort B: AR wide-type CRPC (optional) Currently enrolling patients under Phase 2.
03

Conditions studied

  • Advanced Metastatic Castration Resistant Prostate Cancer

Browse trials for

Keywords

  • mCRPC
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained.
  2. Male aged ≥ 18 years.
  3. confirmed adenocarcinoma of the prostate.
  4. Castration resistant prostate cancer with serum testosterone \<50 ng/dL.
  5. disease.
  6. Ongoing androgen deprivation therapy with GnRH analogue or antagonist, or have had bilateral orchiectomy.
  7. Received at least one prior line of taxane-based chemotherapy and at least one line of hormonal AR targeted therapy (eg, abiraterone, enzalutamide). Patients who have refused or were intolerant to taxane-based chemotherapy may be enrolled.
  8. performance status 0-1.
  9. Adequate marrow, liver and kidney function.
  10. ≤1.5.
  11. Able to swallow study treatment.
  12. Has a of > 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Have a medical condition such as Crohn's disease or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption.
  2. History of pituitary or adrenal dysfunction.
  3. Poorly controlled diabetes mellitus.
  4. abnormality in serum potassium and sodium.
  5. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
  6. Active or unstable cardio-/cerebro-vascular disease, including thromboembolic events.
  7. History of congestive heart failure; cardiac disease, myocardial infarction within 6 months prior to enrollment.
  8. Prolonged interval.
  9. Active infection or other medical condition that would make .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Phase 1 INV-9956 Dose escalation Dose level 1

    INV-9956 Dose escalation Dose level 1 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 1 INV-9956 Dose escalation Dose level 2

    INV-9956 Dose escalation Dose level 2 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 1 INV-9956 Dose escalation Dose level 3

    INV-9956 Dose escalation Dose level 3 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 2 INV-9956 Dose expansion - Cohort A

    INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 2 INV-9956 Dose expansion - Cohort B

    INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 4

    INV-9956 Dose escalation Dose level 4 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 5

    INV-9956 Dose escalation Dose level 5 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

  • Experimental
    Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 6

    INV-9956 Dose escalation Dose level 6 is co-administered with dexamethasone and fludrocortisone acetate

    Drug: INV-9956

Interventions

  • DrugINV-9956

    INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum tolerated dose (MTD)

    The highest dose level at which at least 6 patients have been treated and less than 33% of patients experienced a DLT.

    Time frame: Within first 28 days of treatment

  2. Phase 1: Recommended dose range (RDR)

    The RDR will be determined based on the PK and PD data, the preliminary clinical activity of INV-9956, as well as the incidence rate and nature of the toxicities observed in subsequent cycles beyond Cycle 1

    Time frame: 12 months

  3. Phase 2: Evaluate Radiographic progression-free survival (rPFS)

    To evaluate rPFS per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)

    Time frame: 12 months

  4. Phase 2: Evaluate overall response rate (ORR)

    To evaluate ORR per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)

    Time frame: 12 months

Secondary outcomes

  1. Phase 1: Characterize the safety of INV-9956 as assessed by CTCAE v5.0

    To analyze the safety profile of INV-9956 as a single agent by AE, clinical lab test results, ECG and Vital signs changes

    Time frame: 12 months

  2. Phase 1: Determine the PK using AUC of INV-9956

    To determine the pharmacokinetics (PK) using AUC of INV-9956 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  3. Phase 1: Determine the PK using Cmax of INV-9956

    To determine the pharmacokinetics (PK) using Cmax of INV-9956 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  4. Phase 1: Determine the blood concentration of steroid hormone

    To determine the blood concentration of steroid hormones at various timepoints as PD markers for INV-9956

    Time frame: 12 months

  5. Phase 1: Evaluate Radiographic progression-free survival (rPFS)

    To evaluate rPFS per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)

    Time frame: 12 months

  6. Phase 1: Evaluate overall response rate (ORR)

    To evaluate ORR per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)

    Time frame: 12 months

  7. Phase 2: Characterize the safety of INV-9956 as assessed by CTCAE v5.0

    To analyze the safety profile of INV-9956 as a single agent by AE, clinical lab test results, ECG and Vital signs changes

    Time frame: 12 months

  8. Phase 2: Determine the PK using AUC of INV-9956

    To determine the pharmacokinetics (PK) using AUC of INV-9956 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  9. Phase 2: Determine the PK using Cmax of INV-9956

    To determine the pharmacokinetics (PK) using Cmax of INV-9956 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  10. Phase 2: Determine the blood concentration of steroid hormone

    To determine the blood concentration of steroid hormones at various timepoints as PD markers for INV-9956

    Time frame: 12 months

07

Study locations

15 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 35 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 35 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Sep 23, 2024
StartActual
Jan 23, 2025
Primary completionEst.
Jan 17, 2028
CompletionEst.
Jan 17, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06609005
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Jan 23, 2025
Primary completion
Jan 17, 2028 (estimated)
Completion
Jan 17, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Yi Zhu, MD, MBA
Contact
yi.zhu@ionovabio.com
1 908 240 7514

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion